Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-month, Open-label, Randomized, Multi-center Study of Repaglinide in Combination With Metformin as Compared to Metformin or Repaglinide Given as Monotherapy for the Treatment of Type 2 Diabetes.

NCT01720290 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01720290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01720290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-month, Open-label, Randomized, Multi-center Study of Repaglinide in Combination With Metformin as Compared to Metformin or Repaglinide Given as Monotherapy for the Treatment of Type 2 Diabetes.
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
July 25, 2002
Completion date
February 25, 2003
Enrollment
150 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2